Holen Sie sich die Stockscreener-App
7.87
1.03%
0.08
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by MetLife Investment Management LLC - Defense World
Wells Fargo & Company MN Has $248,000 Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics at Citizens JMP: Strategic Focus on MyPlayfa and Soliprolol - Investing.com
(ZVRA) Trading Advice - news.stocktradersdaily.com
Alucio™ Adds Zevra Therapeutics to its Expanding Base of Life Science Customers - PR Newswire
Zevra Therapeutics Announces Details for Q1 2025 Financial Resul - GuruFocus
Zevra Therapeutics, Inc. to Report First Quarter 2025 Corporate and Financial Results on May 13, 2025 - Nasdaq
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call - GlobeNewswire
Zevra Therapeutics Sets Q1 2025 Earnings Date: Key Details for Rare Disease Portfolio Update - Stock Titan
Zevra Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Invesco Ltd. Has $153,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by JPMorgan Chase & Co. - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Could Be Less Than A Year Away From Profitability - simplywall.st
Are Zevra Therapeutics Inc (ZVRA) shares a good deal now? - uspostnews.com
Zevra Therapeutics to Participate in the Citizens Life Science Conference - The Manila Times
Rare Disease Leader Zevra Therapeutics Reveals Growth Strategy at Citizens Conference - Stock Titan
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Geode Capital Management LLC Has $9.91 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Investment Analysis and Advice - news.stocktradersdaily.com
Zevra calls for stockholder support against board influence bid - Investing.com
Zevra Therapeutics (ZVRA) Prepares for 2025 Annual Meeting, Advocates for Board Stability | ZVRA Stock News - GuruFocus
Zevra calls for stockholder support against board influence bid By Investing.com - Investing.com India
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders | ZVRA Stock News - GuruFocus
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders - The Manila Times
Zevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest Concerns - Nasdaq
ZVRAZevra Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Form DEFC14A ZEVRA THERAPEUTICS, INC. Filed by: ZEVRA THERAPEUTICS, INC. - StreetInsider
ZVRA Stock Sees Surge of Approximately 8.99% in Last Five Days - knoxdaily.com
Zevra Therapeutics (ZVRA) Reveals Key Insights into Niemann-Pick Type C Treatment | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - GlobeNewswire
Breakthrough Study Uncovers MIPLYFFA's Mechanism for Treating Fatal Genetic Disease NPC - Stock Titan
Vanguard Group Inc. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Corebridge Financial Inc. Buys 3,801 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Raymond James Financial Inc. Purchases Shares of 26,916 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Institutional investors may overlook Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) recent US$44m market cap drop as long-term gains remain positive - simplywall.st
Zevra Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher - MarketScreener
Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves - marketscreener.com
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - citybiz
$150M FDA Voucher Sale Transforms Zevra's Financial Position: Rare Disease Success Story - Stock Titan
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline - MSN
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Buy” by Brokerages - Defense World
(ZVRA) Technical Data - news.stocktradersdaily.com
Zevra Therapeutics: Mixed Feelings On Miplyffa Approval (NASDAQ:ZVRA) - Seeking Alpha
Quantbot Technologies LP Sells 7,219 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra therapeutics director Corey Watton buys $2,351 in stock By Investing.com - Investing.com Australia
Zevra therapeutics director Corey Watton buys $2,351 in stock - Investing.com
Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor - MarketScreener
Zevra Therapeutics Files Preliminary Proxy - The Manila Times
Proxy Fight Erupts at Zevra: Former CEO Challenges $150M Cash-Rich Biotech - Stock Titan
Charles Schwab Investment Management Inc. Buys 28,148 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Trend Tracker for (ZVRA) - news.stocktradersdaily.com
John Bode Bought 33% More Shares In Zevra Therapeutics - simplywall.st
Zevra Therapeutics Independent Director Acquires 33% More Stock - Yahoo Finance
Insider Buying: John Bode Acquires Additional Shares of Zevra Th - GuruFocus
Zevra therapeutics director Bode acquires $79,624 in stock By Investing.com - Investing.com Canada
Zevra therapeutics director Bode acquires $79,624 in stock - Investing.com
ZEVRA THERAPEUTICS Director John B Bode Acquires 10,000 Shares - TradingView
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):